Role of Exosomes in Cancer-Related Cognitive Impairment.
Yong Qin KohChia Jie TanYi Long TohSiu Kwan SzeHan Kiat HoCharles L LimoliAlexandre ChanPublished in: International journal of molecular sciences (2020)
A decline in cognitive function following cancer treatment is one of the most commonly reported post-treatment symptoms among patients with cancer and those in remission, and include memory, processing speed, and executive function. A clear understanding of cognitive impairment as a result of cancer and its therapy can be obtained by delineating structural and functional changes using brain imaging studies and neurocognitive assessments. There is also a need to determine the underlying mechanisms and pathways that impact the brain and affect cognitive functioning in cancer survivors. Exosomes are small cell-derived vesicles formed by the inward budding of multivesicular bodies, and are released into the extracellular environment via an exocytic pathway. Growing evidence suggests that exosomes contribute to various physiological and pathological conditions, including neurological processes such as synaptic plasticity, neuronal stress response, cell-to-cell communication, and neurogenesis. In this review, we summarize the relationship between exosomes and cancer-related cognitive impairment. Unraveling exosomes' actions and effects on the microenvironment of the brain, which impacts cognitive functioning, is critical for the development of exosome-based therapeutics for cancer-related cognitive impairment.
Keyphrases
- cognitive impairment
- mesenchymal stem cells
- stem cells
- cerebral ischemia
- cell therapy
- resting state
- white matter
- single cell
- subarachnoid hemorrhage
- bone marrow
- small molecule
- working memory
- bipolar disorder
- depressive symptoms
- multiple sclerosis
- blood brain barrier
- squamous cell carcinoma
- ulcerative colitis
- combination therapy
- case control